FR3061178B1 - Peptides antimicrobiens et leurs utilisations - Google Patents

Peptides antimicrobiens et leurs utilisations Download PDF

Info

Publication number
FR3061178B1
FR3061178B1 FR1663231A FR1663231A FR3061178B1 FR 3061178 B1 FR3061178 B1 FR 3061178B1 FR 1663231 A FR1663231 A FR 1663231A FR 1663231 A FR1663231 A FR 1663231A FR 3061178 B1 FR3061178 B1 FR 3061178B1
Authority
FR
France
Prior art keywords
antimicrobial peptides
peptides
inflammatory diseases
antimicrobial
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1663231A
Other languages
English (en)
Other versions
FR3061178A1 (fr
Inventor
Claire Lacombe
Constance Auvynet
Yvonne Jane Rosenstein
Emmanuelle Sachon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Nacional Autonoma De Mexico Mx
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Universite Paris Saclay
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Pierre et Marie Curie Paris 6
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Sud Paris 11
MEXICO NAC AUTONOMA, University of
Universidad Nacional Autonoma de Mexico
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Pierre et Marie Curie Paris 6, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris Sud Paris 11, MEXICO NAC AUTONOMA, University of, Universidad Nacional Autonoma de Mexico filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR1663231A priority Critical patent/FR3061178B1/fr
Priority to US16/472,447 priority patent/US20230192772A1/en
Priority to EP17838052.3A priority patent/EP3559025A1/fr
Priority to MX2019007390A priority patent/MX2019007390A/es
Priority to PCT/FR2017/053835 priority patent/WO2018115798A1/fr
Publication of FR3061178A1 publication Critical patent/FR3061178A1/fr
Application granted granted Critical
Publication of FR3061178B1 publication Critical patent/FR3061178B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des peptides dotés d'une activité antimicrobienne et/ou anti-inflammatoire, un médicament ou une composition pharmaceutique comprenant de tels peptides, et leur utilisation dans la prévention ou le traitement de maladies inflammatoires, et plus particulièrement des maladies inflammatoires dues ou associées à des infections microbiennes.
FR1663231A 2016-12-22 2016-12-22 Peptides antimicrobiens et leurs utilisations Expired - Fee Related FR3061178B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR1663231A FR3061178B1 (fr) 2016-12-22 2016-12-22 Peptides antimicrobiens et leurs utilisations
US16/472,447 US20230192772A1 (en) 2016-12-22 2017-12-22 Antimicrobial peptides and uses thereof
EP17838052.3A EP3559025A1 (fr) 2016-12-22 2017-12-22 Peptides antimicrobiens et leurs utilisations
MX2019007390A MX2019007390A (es) 2016-12-22 2017-12-22 Peptidos antimicrobianos y usos de los mismos.
PCT/FR2017/053835 WO2018115798A1 (fr) 2016-12-22 2017-12-22 Peptides antimicrobiens et leurs utilisations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1663231 2016-12-22
FR1663231A FR3061178B1 (fr) 2016-12-22 2016-12-22 Peptides antimicrobiens et leurs utilisations

Publications (2)

Publication Number Publication Date
FR3061178A1 FR3061178A1 (fr) 2018-06-29
FR3061178B1 true FR3061178B1 (fr) 2021-02-12

Family

ID=58645166

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1663231A Expired - Fee Related FR3061178B1 (fr) 2016-12-22 2016-12-22 Peptides antimicrobiens et leurs utilisations

Country Status (5)

Country Link
US (1) US20230192772A1 (fr)
EP (1) EP3559025A1 (fr)
FR (1) FR3061178B1 (fr)
MX (1) MX2019007390A (fr)
WO (1) WO2018115798A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2365099C (fr) * 1999-03-17 2012-05-29 University Of Victoria Innovation And Development Corporation Plantes transgeniques resistant a une large variete de pathogenes
AU2007230887A1 (en) * 2006-03-23 2007-10-04 Amylin Pharmaceuticals, Inc. Endothelin and endothelin receptor agonists in the treatment of metabolic diseases
FR2947455B1 (fr) * 2009-07-01 2014-01-03 Centre Nat Rech Scient La dermaseptine b2 comme inhibiteur de la croissance tumorale
EP3384938A1 (fr) * 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Acides nucléiques techniques et leurs procédés d'utilisation

Also Published As

Publication number Publication date
FR3061178A1 (fr) 2018-06-29
MX2019007390A (es) 2019-12-05
WO2018115798A1 (fr) 2018-06-28
EP3559025A1 (fr) 2019-10-30
US20230192772A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
MA53937B1 (fr) Compositions comprenant des souches bactériennes
MA47119B1 (fr) Administration de protéine à base de bactéries à virulence atténuée
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
CY1123189T1 (el) Αντιμικροβiακο πεπτιδιο
MA34002B1 (fr) Thérapie antivirale
UY37789A (es) Nuevos derivados de azaquinolina
BR112016019592A8 (pt) Composto, uso de um composto, e, composição farmacêutica
MA45172B1 (fr) Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
MA43113B1 (fr) Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
EA202190510A1 (ru) Новое лекарственное средство для лечения воспалительной болезни кишечника
MA38369A1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA54936A (fr) Triamtérène ou nolatrexed destinés à être utilisés dans le traitement de la phénylcétonurie
MA42455B1 (fr) Nouveau composé hétérocyclique, procédé de préparation associé et composition pharmaceutique le comprenant
EA202091308A1 (ru) Модифицированный вакцинный штамм brucella для лечения бруцеллеза
FR3081325B1 (fr) Diltiazem pour son utilisation dans le traitement des infections microbiennes
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
BR112022000971A2 (pt) Derivados de di-hidropirimidina e uso dos mesmos no tratamento de infecção por hbv ou de doenças induzidas por hbv
FR3061178B1 (fr) Peptides antimicrobiens et leurs utilisations
BR112022000417A2 (pt) Proteínas de toxina de fusão para tratamento de doenças relacionadas a infecções por cmv
BR112017015474A2 (pt) inibidores de bace1
MA40844A (fr) Compositions pharmaceutiques à action prolongée pour l'hépatite c
EA202092045A1 (ru) Лечение и предупреждение преэклампсии

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20180629

TQ Partial transmission of property

Owner name: SORBONNE UNIVERSITE, FR

Effective date: 20180704

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA, FR

Effective date: 20180704

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FR

Effective date: 20180704

Owner name: UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO, MX

Effective date: 20180704

Owner name: UNIVERSITE PARIS-SUD 11, FR

Effective date: 20180704

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

TQ Partial transmission of property

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA, FR

Effective date: 20201204

Owner name: UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO, MX

Effective date: 20201204

Owner name: SORBONNE UNIVERSITE, FR

Effective date: 20201204

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FR

Effective date: 20201204

Owner name: UNIVERSITE PARIS-SACLAY, FR

Effective date: 20201204

CA Change of address

Effective date: 20210913

ST Notification of lapse

Effective date: 20220808